276 results
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
rodents
I/C
unmodified MSC(M), controls
O
mortality rate
P
patients undergoing total gastrectomy for gastric cancer
I/C
J-pouch (JP) reconstruction, standard Roux-en-Y (RY) esophagojejunostomy
O
dumping syndrome, heartburn symptoms
P
HIV-infected adults with tuberculosis
I/C
Mycobacterium tuberculosis bloodstream infection (BSI), Patients with HIV-associated tuberculosis but without M. tuberculosis BSI
O
Mortality within 30 days
P
Souza ML, Massignan C, Glazer Peres K, Aurélio Peres M
I/C
Systematic review with meta-analysis of data
O
Association between metabolic syndrome and tooth loss
P
Hu ML, Zheng G, Lin H, Yang M, Zhang YD, Han JM
I/C
Desensitizing Toothpastes
O
Dentine Hypersensitivity
P
patients with recurrent or metastatic head and neck squamous cell carcinomas (R/M HNSCC)
I/C
PD-1/PDL-1 inhibitors, anti-EGFR agents, cetuximab, panitumumab, control, platinum-resistant disease, methotrexate, platinum-based regimens
O
overall survival (OS), progression-free survival (PFS), overall response rates (ORR)
P
patients with M. chimaera infection and a prior history of cardiac surgery
I/C
surgical aortic valve replacement or combined aortic valve and root replacement, lethal events
O
better survival
P
patients with eGFR <60 ml/min/1.73 m
I/C
SGLT2 inhibitors, placebo
O
safety outcomes